Literature DB >> 31603988

How and when to use clozapine.

J M Rubio1,2,3, J M Kane1,2,3.   

Abstract

OBJECTIVE: Clozapine is the only approved strategy for treatment-resistant schizophrenia, although it is highly underutilized. We aim to generate practical and actionable evidence-based recommendations for the use of this drug considering prescription barriers.
METHOD: Narrative review.
RESULTS: A consistent body of evidence supports the efficacy of clozapine reducing morbidity and mortality in schizophrenia. The main obstacles to its use are the lack of experience by prescribers and perceived treatment burden. Systematic screening of eligibility, utilization of available resources for consultation, developing a professional network with other stakeholders, as well as optimizing how clozapine is presented to patients is discussed. Furthermore, specific evidence-based recommendations for initiation, maintenance, and safety monitoring with clozapine are provided.
CONCLUSION: Clozapine prescription is one of the areas in psychiatry with the greatest mismatch between efficacy and utilization in clinical practice. Although multiple barriers to the use of clozapine exist, some of these may be overcome by updates of routine clinical practice.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  psychosis; severe mental illness; treatment-resistant schizophrenia

Mesh:

Substances:

Year:  2019        PMID: 31603988     DOI: 10.1111/acps.13111

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  7 in total

1.  Medication Gaps and Antipsychotic Polypharmacy in Previously Hospitalized Schizophrenia Patients: An Electronic Cohort Study in Three Canadian Provinces.

Authors:  Evyn Peters; Arash Shamloo; Rohit J Lodhi; Gene Marcoux; Kylie Jackson; Shawn Halayka; Lloyd Balbuena
Journal:  Front Psychiatry       Date:  2022-06-15       Impact factor: 5.435

2.  Relationship between clozapine exposure and the onset of appendicitis in schizophrenia patients: a retrospective cohort study.

Authors:  Yuta Kawakita; Masahiro Takeshima; Tomonari Komatsu; Aya Imanishi; Dai Fujiwara; Yu Itoh; Kazuo Mishima
Journal:  BMC Psychiatry       Date:  2022-10-21       Impact factor: 4.144

3.  The physical health and side-effect monitoring of patients prescribed clozapine: data from a clinical audit conducted in UK mental health services.

Authors:  Thomas R E Barnes; James H MacCabe; John M Kane; Oriana Delgado; Carol Paton
Journal:  Ther Adv Psychopharmacol       Date:  2020-08-06

Review 4.  Adverse Drug Reactions in Relation to Clozapine Plasma Levels: A Systematic Review.

Authors:  Maria Skokou; Eleni A Karavia; Zoi Drakou; Vassiliki Konstantinopoulou; Christina-Anna Kavakioti; Philippos Gourzis; Kyriakos E Kypreos; Ourania Andreopoulou
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-01

5.  Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation.

Authors:  Maxim Kuzin; Georgios Schoretsanitis; John M Kane; Christoph Hiemke; Michael Paulzen; Ekkehard Haen
Journal:  Clin Pharmacokinet       Date:  2020-10-01       Impact factor: 6.447

6.  Treatment patterns and appropriateness of antipsychotic prescriptions in patients with schizophrenia.

Authors:  Verónica Gamón; Isabel Hurtado; José Salazar-Fraile; Gabriel Sanfélix-Gimeno
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

7.  Clozapine Management in Schizophrenia Inpatients: A 5-Year Prospective Observational Study of Its Safety and Tolerability Profile.

Authors:  Renato de Filippis; Raffaele Gaetano; Georgios Schoretsanitis; Giuseppe Verde; Cesare Anthony Oliveti; John M Kane; Cristina Segura-Garcia; Pasquale De Fazio
Journal:  Neuropsychiatr Dis Treat       Date:  2021-07-01       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.